Sign In | Join Free | My
Search by Category
Wholesale Marketplace
Home > Lab Supplies >

0.5mg / 1ml BP Salbutamol Sulfate Injection Medicine For Bronchospasm Relieve

Categories Injection Medicine
Brand Name: UNP/ Salbutamol
Model Number: 0.5mg/1ml
Certification: GMP
Place of Origin: China
MOQ: 10000boxes
Price: USD0.195-0.205/vial FOB SHANGHAI OR GUANGZHOU
Payment Terms: L/C, T/T, Western Union, D/P, D/A
Supply Ability: 200000vials /MONTH
Delivery Time: 30days after order is setted
Packaging Details: 0.5mg/1ml/ampoule, 100amps/box, 40boxes/carton
Product name: Salbutamol Sulfate Injection
Appearace: A clear colorless or almost colorless liquid
Composition: Each 1ml ampoule contains:0.5mg salbutamol
Indications: 1. For the relief of bronchospasm in bronchial asthmas of all types. 2. Chronic bronchitis. 3. Emphysema.
Assay: >99.0%
Specification: 0.5mg/1ml
Quality standard: BP
Shelf time: 3 years
Package: 0.5mg/1ml/ampoule, 100amps/box, 40boxes/carton
Storage: Store below 25 degrees celsius. Protect from moisture. Keep out of reach of children.
  • Haven't found right suppliers
  • Our buyer assistants can help you find the most suitable, 100% reliable suppliers from China.
  • And this service is free of charge.
  • we have buyer assistants who speak English, French, Spanish......and we are ready to help you anytime!
  • Submit Buying Request
    • Product Details
    • Company Profile

    0.5mg / 1ml BP Salbutamol Sulfate Injection Medicine For Bronchospasm Relieve

    GMP Certified Best Quality BP Salbutamol Sulfate 0.5mg/1ml Injection, Ink prints, relief of bronchospasm in bronchial
    1. Name of the medicinal product

    Salbutamol Sulfate 0.5mg/1ml Injection

    2. Qualitative and quantitative composition

    Each ampoule contains salbutamol sulfate equivalent to 0.5 mg salbutamol.

    3. Pharmaceutical form

    I.M/I.V injection

    4. Clinical particulars
    4.1 Therapeutic indications

    1. For the relief of bronchospasm in bronchial asthmas of all types.
    2. Chronic bronchitis.
    3. Emphysema.
    4.2 Posology and method of administration

    Route of administration Oral.
    The usual effective dose is 4mg three or four times per day. If adequate bronchodilation is not obtained each single dose may be gradually increased to as much as 8mg. However, it has been established that some patients obtain adequate relief with 2mg three or four times daily. In elderly patients or in those known to be unusually sensitive to beta-adrenergic stimulant drugs, it is advisable to initiate treatment with 2mg three or four times per day.
    The following doses should be administered three or four times daily.
    2-6 years: 1-2mg
    6-12 years: 2mg
    Over 12 years: 2-4mg
    The product is not recommended for children under 2 years of age. The drug is well tolerated by children so that, if necessary, these doses may be cautiously increased.
    4.3 Contraindications

    1. Salbutamol should not be used for threatened abortion during the first or second trimester of pregnancy.
    2. Salbutamol and beta-blocking drugs such as propranolol should not usually be prescribed together.
    3. Salbutamol tablets are contraindicated in patients with a history of hypersensitivity to any of their components.
    4.4 Special warnings and precautions for use

    Patients with rare hereditary problems of galactose intolerance, the lapp lactase deficiency or glucose – galactose malabsorption should not take this medicine.
    Bronchodilators should not be the only or main treatment in patients with severe or unstable asthma.
    Increasing use of bronchodilators in particular short-acting inhaled beta2-agonists to relieve symptoms indicates deterioration of asthma control. If patients find that short acting relief bronchodilator treatment becomes less effective or they need more inhalations than usual, medical attention must be sought.
    Salbutamol causes peripheral vasodilation which may result in reflex tachycardia and increased cardiac output
    Salbutamol should only be administered cautiously to patients suffering from thyrotoxicosis after careful evaluation of the benefits and risks of treatment.
    Constant monitoring of potassium levels in patients with severe asthma is essential, potentially serious hypokalaemia may result from beta-2 agonist therapy.
    Administration of beta agonists is associated with a rise of blood glucose. Therefore blood glucose and lactate levels should be monitored in diabetics and diabetic treatment adjusted accordingly to meet the needs of the diabetic during tocolysis (see section 4.5). Diabetic patients may be unable to compensate for the increase in blood glucose and the development of ketoacidosis has been reported.
    Concurrent administration of corticosteroids can exaggerate this effect.
    Cardiovascular effects may be seen with sympathomimetic drugs, including salbutamol. There is some evidence from post-marketing data and published literature of myocardial ischaemia associated with beta agonists.
    Respiratory indications
    Patients with underlying severe heart disease (e.g. ischaemic heart disease, arrhythmia or severe heart failure) who are receiving salbutamol should be warned to seek medical advice if they experience chest pain or other symptoms of worsening heart disease. Attention should be paid to assessment of symptoms such as dyspnoea and chest pain, as they may be of either respiratory or cardiac origin.

    4.5 Interaction with other medicinal products and other forms of interaction

    The effects of salbutamol may be altered by guanethidine, reserpine, methyldopa, tricyclic antidepressants and monoamine oxidase inhibitors.
    There is an increased risk of hypokalaemia if high doses of theophylline or high doses of corticosteroids are given with higher doses of salbutamol.
    Halogenated anaesthetics
    Owing to the additional antihypertensive effect, there is increased uterine inertia with risk of haemorrhage; in addition, serious ventricular rhythm disorders due to increased cardiac reactivity, have been reported on interaction with halogenated anaesthetics. Treatment should be discontinued, whenever possible, at least 6 hours before any scheduled anaesthesia with halogenated anaesthetics.
    The administration of beta-agonists is associated with a rise of blood glucose, which can be interpreted as an attenuation of anti-diabetic therapy; therefore individual anti-diabetic therapy may need to be adjusted (see section 4.4).
    Potassium depleting agents
    Owing to the hypokalaemic effect of beta-agonists, concurrent administration of serum potassium depleting agents known to exacerbate the risk of hypokalaemia, such as diuretics, digoxin, methyl xanthines and corticosteroids, should be administered cautiously after careful evaluation of the benefits and risks with special regard to the increased risk of cardiac arrhythmias arising as a result of hypokalaemia (see section 4.4).
    4.6 Pregnancy and lactation

    Salbutamol should only be used during pregnancy if it is considered essential by the physician.
    As salbutamol is probably secreted in breast milk its use in nursing mothers requires careful consideration. It is not known whether salbutamol has a harmful effect on the neonate, and so its use should be restricted to situations where it is felt that the expected benefit to the mother is likely to outweigh any potential risk to the neonate.
    4.7 Effects on ability to drive and use machines

    None known.
    4.8 Undesirable effects

    The only side effect of significance is a fine tremor of skeletal muscle, which occurs in some patients, usually the hands and the effects are dose related. A few patients feel tense; this is also due to the effects on skeletal muscle and not to direct CNS stimulation. With doses of salbutamol higher than those recommended or in patients who are unusually sensitive to beta-adrenergic stimulants, peripheral vasodilation and a compensatory increase in heart rate may occur.
    Occasionally headaches have been reported. Lactic acidosis, myoclonus, pulmonary oedema, hypokalaemia, cardiac arrhythmias may also occur and very rarely hypersensitivity reactions including angioedema, urticaria, bronchospasm, hypotension and collapse.
    There have been spontaneously reports of myocardial ischemia in post-marketing experience (frequency unknown, see section 4.4).
    4.9 Overdose

    The preferred antidote for overdosage with salbutamol is a cardioselective beta blocking agent, but beta blocking drugs should be used with caution in patients with a history of bronchospasm.
    Hypokalaemia may occur following overdose with salbutamol. Serum potassium levels should be monitored.

    5. Pharmacological properties
    5.1 Pharmacodynamic properties

    Salbutamol is a selective Beta-2-adrenergic agonist administered for the symptomatic relief of bronchospasm associated with chronic or acute asthma, bronchitis or other obstructive pulmonary diseases. Because of its relative specificity for β2receptors, salbutamol relaxes smooth muscle of the bronchi, uterus and vascular supply to the skeletal muscle, but generally has much less stimulant action on the heart than does isoproterenol which has powerful action on all beta receptors.
    5.2 Pharmacokinetic properties

    Salbutamol is readily absorbed from the gastrointestinal tract. Its effects occur within 15 minutes and last for about 14 hours. The drug is excreted in urine in about 24 hours, 50% of the drug being excreted within 4 hours. The peak plasma concentration of salbutamol and its metabolites is 5.1-11.7μg% at 2.5-3 hours after an oral dose of 4mg. Salbutamol does not cross the blood brain barrier to a significant extent, but it crosses the placental barrier.
    5.3 Preclinical safety data

    None stated.

    6. Pharmaceutical particulars
    6.1 List of excipients

    The tablets also contain: maize starch, lactose monohydrate, dispersed pink (erythrosine (E127), carmoisine (E122), titanium dioxide (E171)), sodium starch glycollate, talc, magnesium stearate.
    6.2 Incompatibilities

    None known.
    6.3 Shelf life

    2 years
    6.4 Special precautions for storage

    Store below 25°C in a dry place.
    6.5 Nature and contents of container

    Polypropylene tubes with low density polyethylene caps. Packing material: high density polyethylene film.
    28s, 30s, 56s, 60s, 84s, 100s, 250s, 500s, 1000s
    Polyethylene container with a polypropylene lid.
    6.6 Special precautions for disposal and other handling

    None stated.

    Quality 0.5mg / 1ml BP Salbutamol Sulfate Injection Medicine For Bronchospasm Relieve for sale
    Send your message to this supplier
    Enter your email please.
    To: Wuhan uni-pharma bio-tech co.,ltd
    Characters Remaining: (0/3000)
    Inquiry Cart 0

    Home| Products| Suppliers| Quality Suppliers| Site Map |About Us |Contact Us |Help |关于我们 |联系我们

    Copyright © 2009 - 2018 All rights reserved.